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Abstract 13 
Niemann-Pick type C1 (NPC1) receptor is an endosomal membrane protein that 14 
regulates intracellular cholesterol trafficking, which is crucial in the Ebola virus 15 
(EBOV) cycle. The severe acute respiratory syndrome coronavirus 2 (SARS-16 
CoV-2) enters the cell by binding of the viral spike (S) protein to 17 
the ACE2 receptor. This requires S-protein processing either by the 18 
surface transmembrane serine protease TMPRSS2 for plasma membrane fusion 19 
or cathepsin L for endosomal entry. Additional host factors are required for viral 20 
fusion at endosomes. Here, we report a novel interaction of the SARS-CoV-2 21 
nucleoprotein (N) with the cholesterol transporter NPC1. Moreover, small 22 
molecules interfering with NPC1 that inhibit EBOV entry, also inhibited human 23 
coronavirus. Our findings suggest an important role for NPC1 in SARS-CoV-2 24 
infection, a common strategy shared with EBOV, and a potential therapeutic 25 
target to fight against COVID-19. 26 
 27 
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To date, the COVID-19 pandemic has caused over one million of deaths and 32 
affected over 73-millions of people around the world (1). COVID-19 is caused by 33 
the emerging and pathogenic severe acute respiratory syndrome coronavirus 2 34 
(SARS-CoV-2) first reported in the city of Wuhan (China) as a rare pneumonia 35 
(2, 3) that rapidly spread worldwide. A better understanding of the biology of 36 
SARS-CoV-2 is vital in order to develop effective therapeutics.  37 
A key step of the biology of SARS-CoV-2 is the cell entry mechanism. Viral entry 38 
involves the activation of its trimeric spike glycoprotein by TMPRSS2 protease 39 
upon interaction with the angiotensin-converting enzyme 2 (ACE2) receptor at 40 
the plasma membrane to mediate fusion (4-8). Also, the virus can enter via 41 
endosomes under cathepsin L processing, similar to SARS-CoV-1 (7, 9). In fact, 42 
the inhibition of both alternative entries is necessary for full inhibition of SARS-43 
CoV-2 entry (10, 11). Other cellular proteases facilitate SARS-CoV-2 cell tropism, 44 
like furin, possibly at a post-binding step (12, 13). 45 
Considering that SARS-CoV-2 may enter the cell by endocytosis, it would be 46 
partially acid pH dependent and should exit endosomes by fusion to start 47 
replication (13). SARS-CoV-2 replication occurs in the cytoplasm at double 48 
membrane vesicles of possible origin in the endoplasmic reticulum, which provide 49 
support to the viral RNA replication and transcription complex (14-16). 50 
SARS-CoV-2 endosomal pH-dependent masking through endosomal cleavage 51 
was recently described (8). Similarly, endosomal processing of the Ebola virus 52 
(EBOV) glycoprotein trimer enhances infectivity and evidence a conformational 53 
masking of the receptor binding site of this protein (17, 18). A similar process has 54 
been described for the human immunodeficiency virus (HIV) envelope trimer (19). 55 
Therefore, the similarities found between these viruses were the start point of this 56 
work. EBOV enters the cell using the endocytic pathway, and its entry is mediated 57 
by the viral glycoprotein (GP), which decorates the viral surface organized in 58 
trimeric spikes (20). The GP is then processed by endosomal cathepsins to 59 
remove its heavily glycosylated C-terminal residues and the glycan cap. This 60 
removal produces the cleaved form of the N-terminal receptor binding subunit 61 
GP1 (GPCL) that is required to mediate fusion at the endosomal membrane. Two 62 
simultaneous publications described first that the endosomal receptor called 63 
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NPC1 is an intracellular host receptor for EBOV (21, 22). Since then, the 64 
relevance of NPC1 on viral infections have been shown for different viruses 65 
including HIV (23), Hepatitis C (HCV) (24, 25), Chikungunya virus (CHIKV) (26)  66 
and several Flaviviruses such as Dengue (DENV) (27, 28) and ZIKA virus (29)  67 
among others (26, 30). 68 
 69 
Given SARS-CoV-2 can be internalized via clathrin- and non-clathrin-mediated 70 
endocytosis; some researchers hypothesized a role for NPC1 in SARS-CoV-2 71 
infection that remains to be determined (31-34). Due to the increasing relevance 72 
of this molecule, we designed our study to investigate the potential binding of 73 
SARS-CoV-2 proteins to NPC1, according to the existing evidence of SARS-74 
CoV-2 endosomal passage (35). 75 
  76 
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Materials and Methods 77 
 78 
Cell culture and viruses   79 
Human embryonic kidney cells 293T/17 (HEK 293T; ATCC-CRL-11268) were 80 
cultured in Dulbecco modified Eagle medium (DMEM) at 37 ºC and 5% CO2 81 
atmosphere, supplemented with 100 IU/ml penicillin, 100 µg/ml streptomycin, 1X 82 
GlutaMAX (Thermo Fisher) and 10% heat-inactivated fetal bovine serum (FBS). 83 
Huh-7 Lunet C3 cells, a gift from T. Pietschman (Twincore, Germany), were 84 
cultured at 37 ºC in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 85 
with 100 IU/ml penicillin, 100 µg/ml streptomycin, 10mM HEPES, 1X NEAA and 86 
10% of heat-inactivated fetal bovine serum (FBS). 87 
For virus infections, we used common cold coronavirus 229E, which expresses 88 
the green fluorescent protein (GFP) gene (229E-GFP) (36). This recombinant 89 
virus was kindly given by V. Thiel, at the University of Bern, in Switzerland. The 90 
infection experiments were conducted at 33°C and 5% CO2. 91 
 92 
Design and construction of plasmid that express the SARS-CoV-2 N tag to 93 
EGFP. 94 
The methodology used in this part of the study was previously used in Garcia-95 
Dorival et al., 2016 (37). To generate the SARS-CoV-2 N with N-terminal EGFP 96 
tag (EGFP-N), a codon optimized cDNA sequence for the ORF of SARS-CoV-2 97 
N (NCBI reference sequence number: NC_045512) was cloned into the pEGFP-98 
C1 (by GeneArt-Thermo Fisher Scientific). Once cloned, the sequence of the 99 
plasmid EGFP-N was confirmed by sequencing (Gene Art–Thermo Fisher 100 
Scientific). 101 
 102 
Expression of tagged-N protein and EGFP in HEK 293T cells. 103 
To transfect HEK 293T cells, four 60mm dishes were seeded with 2.5 x106 cells 104 
each 24 hours prior to transfection in DMEM complete medium described above. 105 
Then, a transfection of EGFP or EGFP-N was done using Lipofectamine 2000 106 
(Thermo Fisher Scientific), following the instructions of the manufacturer. Twenty-107 
four hours post transfection the cells were harvested, lysed and 108 
immunoprecipitated using a GFP-Trap kit (Chromotek). 109 
 110 
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Immunoprecipitations (IP) 111 
EGFP-N and EGFP immunoprecipitations (IP) were done using a GFP-Trap_A 112 
(Chromotek). To do the IPs, the cell pellet was resuspended in 200μl of lysis 113 
buffer (10mM Tris/Cl pH 7.5; 150mM NaCl; 0.5mM EDTA; 0.5%NP40) and then 114 
incubated for 30 minutes on ice. The lysate was then clarified by centrifugation at 115 
14000 x g and diluted five-fold with dilution buffer (10mM Tris/Cl pH 7.5; 150mM 116 
NaCl; 0.5mM EDTA). The GFP-Trap agarose beads were equilibrated with ice-117 
cold dilution buffer and then incubated with diluted cell lysate overnight at 4°C on 118 
a rotator, followed by centrifugation at 2700 x g for 2 minutes. The bead pellet 119 
was wash two times with wash buffer (10mM Tris/Cl pH 7.5; 150mM NaCl; 0.5mM 120 
EDTA). After removal of wash buffer, the beads were resuspended in 100μl of 121 
Sample Buffer, Laemmli 2X Concentrate (Sigma Aldrich) and boiled at 95 for ten 122 
minutes to elute the bound proteins. Buffers used for Immunoprecipitations were 123 
all supplemented with HaltTM Protease Inhibitor Cocktail EDTA-Free (Thermo 124 
Fisher Scientific). 125 
 126 
Co-Immunoprecipitation (Co-IP) 127 
Similar to what was described in Garcia-Dorival et al, 2016 (37), Co-IP for NPC1 128 
was performed using 50μl of the Immobilized Recombinant Protein G Resin 129 
(Generon) and specific antibodies against NPC1 (Abcam, ab108921). The cell 130 
pellets were incubated for 30 minutes on ice with 200μl lysis buffer. The lysate 131 
was then clarified by centrifugation and diluted five-fold with dilution buffer prior 132 
to adding 2g of the primary antibody and then incubated at 4°C on a rotator for 133 
two hours. The protein G resin (Generon) were equilibrated with ice-cold dilution 134 
buffer and then incubated at 4°C on a rotator with diluted cell lysate containing 135 
the antibody overnight at 4°C on a rotator, followed by centrifugation at 2500 x g 136 
for 2 minutes to remove non-bounds fractions. The wash and elution steps were 137 
performed as describe previously in GFP co-immunoprecipitation. 138 
 139 
Western blot analysis  140 
To do confirm the expression of GFP and GFP-N proteins, an SDS-PAGE and a 141 
western blot (WB) was done. For the SDS-PAGE, a Mini-PROTEAN TGX Gels 142 
were used (Bio-Rad 4561096), then, the gels were transferred to PVDF 143 
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membranes using the Trans-Blot Turbo Transfect Pack (Bio-Rad 1704159) and 144 
the Trans-Blot Turbo system (Bio-Rad). Following this, the transferred 145 
membranes were then blocked in 10% skimmed milk powder dissolved in TBS-146 
0.1% Tween (TBS-T) (50mM Tris-HCl (pH8.3), 150mM NaCl and 0.5% (v/v) 147 
Tween-20) buffer for one hour at room temperature. Primary antibody was diluted 148 
1:1000 in blocking buffer and then incubated at 4C overnight. After three 149 
washes, blots were incubated with appropriate HRP secondary antibody diluted 150 
in blocking buffer at a 1:5000 for 1 hour at room temperature. Blots then were 151 
developed using enhanced chemiluminescence reagent (Bio-Rad) and detected 152 
with ChemiDoc™ XRS Gel Imaging System using Image Lab™ software (Bio-153 
Rad).  154 
 155 
Production of SARS-CoV-2 N protein in the baculovirus system 156 
The sequence of the N protein published in the NCBI database was selected 157 
(GenBank accession number: 43740575 / NCBI reference sequence number: 158 
NC_045512). The codon usage of the N encoding gene was optimized for its 159 
expression in insect cells (OptimumGene™-Codon Optimization algorithm) and 160 
the coding sequence for this protein was synthesized by the company GenScript. 161 
The donor plasmid pFastBac1 containing an expression cassette expressing the 162 
recombinant protein under the control of the polyhedrin promoter was obtained. 163 
The Bacmid for the generation of the baculovirus was prepared in E. Coli 164 
DH10Bac bacterial cells containing the mini-Tn-7-replicon. Bacmids were 165 
transfected in the regulatory Sf9 cells and a viral clone selection was made by 166 
two rounds of plaque cloning to obtain the working virus stock. The baculovirus 167 
genome region was sequenced to determine the integrity of the N gene in the 168 
recombinant baculovirus named rBacN. 169 
 170 
SARS-CoV-2 N protein production in pupae 171 
The production of SARS-CoV-2 N protein in insect pupae (Tricoplusia ni; T. ni) 172 
was performed as previously described (38). Briefly, pupae were allocated in the 173 
inoculation robot that dispensed a maximum of 5 μl with the baculovirus titers 174 
protein in 5 days pupae incubation time in constant temperature and humidity 175 
chambers. After that period, pupae were collected and stored frozen, before 176 
downstream processing. T.ni pupae containing the recombinant protein were 177 
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homogenized in extraction buffer. Then, subsequent steps of clarification, 178 
diafiltration and His-tag purification were carried, out in order to obtain purified 179 
SARS-CoV-2 N protein. Protein concentration, yield and level of purity were 180 
determined by SDS-PAGE analysis using 4–20 % or 12 % Mini-Protean TGX 181 
precast gels from Bio-Rad. Gels were stained with QC Colloidal stain (3 ng 182 
sensitivity) in the case of concentration and yield evaluation and with SYPRO 183 
Ruby (1 ng sensitivity) in the case of level purity analysis, both from Bio-Rad. 184 
Recombinant SARS-CoV-2 N protein produced in pupae was measured by band 185 
densitometry with the ChemiDoc™ XRS Gel Imaging System using Image Lab™ 186 
software (Bio-Rad). A BSA standard curve was used for quantification. 187 
 188 
ELISA assays 189 
High-binding 96-well ELISA plates (Nunc) were coated with 0.5 µg/well of purified 190 
SARS-CoV-2 N protein in carbonate/bicarbonate buffer 0.05 M pH 9.6 and 191 
allowed to bind over night at 4ºC. Then, endogenous human NPC1 and HSP90 192 
were purified using immobilized Recombinant Protein G Resin (Generon) and 4 193 
µg of specific antibodies against NPC1 (Abcam, ab108921) or HSP90 (Enzo Life 194 
Sciences, ADI-SPA-835) respectively. All steps were performed as described in 195 
Co-IP assays. Serial dilutions of these endogenous NPC1 and HSP90 were 196 
added to the plate and capture was allowed to proceed for 1 hour at 37ºC. After 197 
that, plates were washed with PBST (PBS 0.1%Tween20) and the binding of 198 
NPC1 to SARS-CoV-2 N protein was detected with a rabbit anti-NPC1 antibody 199 
(1:2000), revealed with an anti-rabbit-horseradish peroxidase (HRP) (1:2000) 200 
using a colorimetric substrate (OPD) and finally, quantified by absorbance at 492 201 
nm in the EnSight multimode plate reader of PerkinElmer. Effect of the 202 
compounds on the binding was performed pre-incubating 50 µM and 100µM of 203 
each compound with NPC1 1h a 37ºC before adding it to the plate. 204 
 205 
Compounds studied 206 
All the compounds tested in this work have a purity ≥95% by HPLC. SC 207 
compounds were synthesized at Centro de Investigaciones Biológicas (CIB-208 
CSIC) following described procedures. All these molecules were included in the 209 
MBC chemical library and some of them were previously characterized as 210 
potential inhibitors of the protein-protein interaction between NPC1 and EBOV-211 
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GP (39, 40). The compounds tested in this study are shown in Figure 2 and were 212 
resuspended in DMSO at 50 mM. Sulfides SC198 and SC073, and carbazole 213 
SC816, were used at working concentrations of 5, 50 and 50 µM; 214 
benzothiazepines SC397, SC593, SC567, at working concentrations of 75 µM 215 
and SC338 at 100 µM respectively. The first three compounds were shown 216 
previously to be active against EBOV while the others were inactive (40). 217 
Compounds MBX2254 and MBX2270 were used as gold standards as they have 218 
been reported to inhibit EBOV-GP/NPC1 interaction with high selectivity (41). 219 
These compounds were purchased from MolPort and used at concentrations of 220 
75 µM and 25 µM, respectively. Class II cationic amphiphilic compound U18666A 221 
is a drug that blocks cholesterol flux out of lysosomes and also inhibits Ebola 222 
virus infections. It was acquired from Sigma-Aldrich and used at 10µM (42). 223 
Imipramine, a hydrophobic amine and FDA-approved antidepressant drug was 224 
acquired from Sigma-Aldrich and used at 25 µM (26, 43). 225 
 226 
Cytotoxicity assays 227 
Huh-7 cells were seeded in 96-well plates and incubated with DMEM containing 228 
each compound at concentrations ranging from 0 to 100 µM. After 24 hours, cell 229 
viability was measured by Cell Titer 96 AQueous Non-Radioactive Cell 230 
Proliferation Assay (Promega) following the manufacturer´s instructions. 231 
Absorbance was measured at 490 nm using an ELISA plate reader.  232 
Cell viability was reported as the percentage of absorbance in treated cells 233 
relative to DMSO- treated cells (Figure S3). The 50% cytotoxic concentration 234 
(CC50) was calculated and non-toxic working concentrations (over 80% cell 235 
viability) used to test the activities of these compounds on CoV infection. 236 
The values of the half maximal inhibitory concentration (IC50) inhibition of the 237 
infection presented on Figure 3 table correspond to the mean of 3 independent 238 
experiments. The IC50s values and dose-response curves were estimated using 239 
GraphPad Prism v6.0 with a 99% confidence interval. 240 
 241 
Flow cytometry analysis  242 
Detection of CoV infected cells was performed by flow cytometry. Huh-7 cells 243 
were pre-treated with compounds at the indicated concentrations in growth 244 
medium for 1 h at 33 ºC, followed by infection with 229E-GFP at a multiplicity of 245 
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infection (MOI) of 1 pfu/cell for 24 h. Cells were washed twice with growth medium 246 
after 90 min of adsorption at 33˚C, and incubated with DMEM 10% 24 h. Cells 247 
were then harvested with PBS-EDTA 5mM, and diluted in PBS. Detection of 248 
229E-GFP infected cells was performed by analyzing GFP expression. In order 249 
to determine the percentage of infected cells per condition, 8,000 cells/time point 250 
were scored using FACS Canto II flow cytometer (BD Sciences) and analyzed 251 
using the FlowJo software. Untreated control infected cultures yielded 75–90% 252 
of infected cells from the total cells examined. Infected cell percentages obtained 253 
after drug treatments were normalized to DMSO values. 254 
 255 
Statistical analysis 256 
The experimental data was analyzed by one-way ANOVA by Graph Pad Prism 6 257 
software. For multiple comparisons, Bonferroni´s correction was applied. Values 258 
were expressed in graph bars as mean ± SD of at least three independent 259 
experiments unless otherwise noted. A p value ˂0.05 was considered as 260 
statistically significant. 261 
262 
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Interaction of SARS-CoV-2 N protein with NPC1 265 
To investigate the interaction of SARS-CoV-2 Nucleoprotein (N) with NPC1, N 266 
protein was expressed as an EGFP-fusion protein in HEK 293T cells. Then, 267 
proteins were extracted from lysed cells and assayed for immunoprecipitation (IP) 268 
using a high affinity EGFP immunoprecipitation kit (GFP-Trap). Finally, protein 269 
expression/interaction was confirmed by fluorescence and western blot analysis 270 
(Figure 1A and 1C). This pipeline (Figure 1B) has been used to detect protein 271 
interacting partners for other RNA virus such as EBOV (37, 44). HEK 293T cells 272 
were selected due to their high efficiency of transfection, being the cell line of 273 
choice for protein-protein interaction studies of several viruses including SARS-274 
CoV-2 (45). 275 
Protein expression of EGFP-N and EGFP alone was confirmed using western 276 
blot analysis and fluorescence (Figure 1A and 1C). The efficiency of transfection 277 
for both plasmids was approximately 80% (Figure 1A). EGFP-N and EGFP were 278 
then immunoprecipitated using an EGFP-Trap. After immunoprecipitation, both 279 
input (cell lysate) and bound (or elution) samples were analysed by western blot. 280 
Proteins corresponding to the molecular weight of EGFP-N (70 kDa) and the 281 
EGFP empty (27 kDa) were detected using an anti-EGFP antibody (Figure 1C). 282 
NPC1, as an endogenous protein, was also detected in both input samples 283 
(EGFP-N and EGFP); but only in the bound fraction of EGFP-N sample (Figure 284 
1C). This experiment was repeated three times to ensure reproducibility 285 
(Supplementary figure S1A).  286 
To further validate a specific interaction between EGFP-N and NPC1, two cellular 287 
proteins were selected as negative controls. In this case, HSP90 chaperone and 288 
endosomal protein EEA1 were used as controls given the abundance of these 289 
proteins in cells (Figure 1C).  290 
 291 
Validation of SARS-CoV-2 N interaction with NPC1  292 
Co-immunoprecipitations against NPC1 (or reverse pull down) were performed 293 
to confirm and further validate the interaction between SARS-CoV-2 N and 294 
NPC1. SARS-CoV-2 N was overexpressed in HEK 293T cells and then cellular 295 
extracts were analysed by co-immunoprecipitation using protein G-beads and 296 
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specific monoclonal antibodies against NPC1 (Figure 1B). Bound samples 297 
obtained from the co-immunoprecipitations were then analysed by western blot, 298 
which confirmed the presence of SARS-CoV-2 N (Figure 1D). As a result of this 299 
interaction, we hypothesized that NPC1 might have an important function in virus 300 
biology. 301 
 302 
Figure 1. Immunoprecipitation analysis of SARS-CoV 2 N protein with endogenous NPC1. 303 
A. Expression of SARS-CoV-2 Nucleoprotein. Immunofluorescence of HEK 293T cells transiently 304 
expressing EGFP at the upper panel and EGFP-N protein at the lower panel showing different distribution 305 
as expected. GFP, Topro3 and Merge are indicated in upper panels in different colours. The scale bar 306 
indicates 25 µm. B. Schematic representation of the methodology used in this study for immunoprecipitation. 307 
C, D. Detection of SARS-CoV-2 N fussed to GFP, GFP control and cellular proteins analysed in the 308 
immunoprecipitation assay by western blot. C. Endogenous NPC1, EEA1, HSP90; and transfected EGFP-309 
N and EGFP control were detected at the expected molecular weights. D. Endogenous NPC1, HSP90 and 310 
transfected EGFP-N and EGFP control were detected at the expected molecular weights from samples 311 
collected from the co-immunoprecipitations (reverse pulldown). Molecular weighs: NPC1~175kD, 312 
EEA1~110kD, HSP90~75kD, EGFP-N~70kD, EGFP~27kD. 313 
 314 
Functional assays 315 
For an orthogonal characterization of the interaction, we used NPC1 inhibitor 316 
drugs to inhibit human coronavirus (HCoV) infection. To do this, Huh-7 cells were 317 
treated with the inhibitor compounds for an hour at different concentrations and 318 
then, infected with HCoV 229E-GFP recombinant virus at a MOI of 1 pfu/ml. Cells 319 
were then analysed at 16 hpi.  320 
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Figure 2. Chemical structure of small molecules used in this study.  323 
 324 
Inhibitors MBX2254 and MBX2270 (Figure 2) were selected as they target NPC1 325 
with high selectivity and both have been described to inhibit HIV-pseudotyped-326 
EBOV-GP binding to NPC1 (41). MBX2254 and MBX2270 were used at 75 and 327 
25 µM, respectively. We also used imipramine, a Food and Drug Administration 328 
(FDA)-approved drug, that inhibits EBOV and other viruses due to its ability to 329 
induce a phenotype similar to NPC1 deficiency (46).  330 
Finally, we assayed a set of compounds initially selected by virtual screening of 331 
the MBC chemical library in the EBOV-GP/NPC1 interaction (40). These 332 
compounds were previously found to inhibit infection with EBOV pseudotyped 333 
retrovirus and some of them - sulfides and carbazoles - were able to disturb the 334 
NPC1-GP interaction in an ELISA assay. Compounds were classified in three 335 
chemical classes, sulfides SC198 and SC073, and carbazole SC816 used at 5, 336 
50 and 50 µM respectively; and benzothiazepines SC397, SC593, SC567 (Figure 337 
2), that were used at 75 µM, or 100 µM of SC338. Noteworthy, sulfides and 338 
carbazoles were found to potentially act through inhibition of NPC1-GP 339 
interaction, while benzothiazepines do not affect this interaction (40). Based on 340 
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these previous results, the three classes were included in this study for 341 
comparative purposes. As a reference, we used U18666A compound (10 µM), 342 
known to inhibit cholesterol transport function of NPC1 and the infectious entry of 343 
several viruses including EBOV and ASFV (23, 26, 42).  344 
We detected that MBX2270 derivative potently inhibited HCoV infection (50% 345 
inhibitory concentration IC50= 3.26 µM, selectivity index 28.36; Figure 3). In 346 
general, our results yielded significant inhibition >99% of HCoV infection with the 347 
U18666A compound and imipramine treatment and with sulfides from the library 348 
compounds (Figure 3A). Others yielded over 80% of infectivity inhibition (except 349 
for SC397 and SC338; Figure 3B). IC50 was <1 µM in several sulfide compounds 350 
(SC073 IC50= 0.53 µM, Index 151.47), U18666A (IC50 0.1 µM, Index 362.34) and 351 
imipramine (FDA085; IC50= 0.75 µM, Index 72.3). Full information of 352 
dose/response curves for these chemicals are included in Supplementary Fig. 353 
S4.  354 
 355 
Figure 3. Activity of small-molecule inhibitors of NPC1 and related compounds against HCoV. A. 356 
Infectivity percentages of HCoV 229E-GFP in Huh-7 cells at 24 hpi. Y axis depicts GFP fluorescence 357 
intensity in controls and cells pretreated 1 h before infection with selected compounds at the concentrations 358 
above described (**p < 0.001; ***p < 0.0001). B. IC50 values (µM) were determined for these compounds. 359 
For determination of CC50 values, cells were treated with compound alone, and values (µM) were determined 360 
from linear portions of the dose-response curves shown in Supplementary Figure S4. SI, selectivity index 361 
(CC50/IC50).  362 
 363 
In addition to these functional experiments, we also tested the ability of these 364 
compounds to disrupt the NPC1/SARS-CoV-2 N protein interaction in an ELISA 365 
assay, as described in Materials and Methods. First, we tested increasing 366 
concentrations of NPC1 and control protein HSP90 in plates coated with SARS-367 
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CoV-2 N protein. We detected a positive reaction with increasing concentrations 368 
of NPC1, while negative control HSP90 remained unaltered (Figure 4A). Then, 369 
we analysed the inhibition of NPC1/SARS-CoV-2 N binding with a sample of the 370 
compounds previously described in this study. We obtained a significant inhibition 371 
of this specific binding in those samples tested with one inhibitor compound from 372 
each class 100 µM SC073 and 50 or 100 µM of MBX2270 (Figure 4B).  373 
 374 
Figure 4: Inhibition of NPC1 binding to N protein by chemicals in an ELISA assay. A. Binding of 375 
increasing concentrations of NPC1 or HSP90 to N protein. HSP90 was used as a negative control. 376 
Concentrations analyzed were 5, 2.5, 0.5, 0.1 or 0.05 µg. B. DMSO or 50/100 µM chemical compounds 377 
were incubated with 5 µg of purified endogenous NPC1 before being added to ELISA plates previously 378 
coated with purified N protein (0.5 µg/well). Then, the binding of purified NPC1 protein to viral N protein was 379 
determined with an anti-NPC1 antibody revealed with an anti-rabbit-HRP. Absorbance was measured at 492 380 
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Current COVID-19 pandemic has affected millions of people all around the globe 388 
and has been one of the mayor challenges in this century due to a great loss of 389 
lives and significant economic losses (1). This highlights an urgent need for 390 
developing efficient therapeutics against SARS-CoV-2 since there is no licensed 391 
treatment available. 392 
 393 
There are several pathogenic viruses, that are known to use the endocytic 394 
pathway to enter the cell, the most important being EBOV. Two publications 395 
described simultaneously that the endosomal protein called NPC1 or Niemann-396 
Pick type C1 is a host receptor for EBOV (21, 22). EBOV entry is mediated by 397 
the viral glycoprotein (GP) which is organized in trimeric spikes at the viral surface 398 
(20). NPC1 binding requires the processing of viral GP. GP cleavage by 399 
endosomal cathepsins unmasks the binding site for NPC1 by removing heavily 400 
glycosylated C-terminal residues and the glycan cap to produce the cleaved form 401 
of the N-terminal receptor binding subunit GP1 (GPCL). Finally, GPCL-NPC1 402 
binding within endosomes is required to mediate fusion and viral escape into the 403 
host cytoplasm (21, 22) as a second intracellular receptor (47). 404 
Thereby, NPC1 could be used as an important druggable target (22) on viral 405 
infection. An example of this is compound U18666A, which blocks intracellular 406 
cholesterol efflux mediated by NPC1, along with imipramine severely impacts 407 
EBOV (22, 42, 43) and other viruses like HIV (23) and DENV (27, 28), CHIK (26), 408 
ZIKV (29) and other Flavivirus. Knockdown or chemical impairment of NPC1 409 
severely reduced cholesterol supply at the Hepatitis C virus replication sites 410 
altering the replication membranous web (25). 411 
 412 
SARS-CoV-2 infection starts with the interaction between spike glycoprotein (S) 413 
with the ACE2 cellular receptor. It requires activation by the TMPRSS2 at the 414 
plasma membrane. TMPRSS2 is located at the vicinity of ACE2 in lipid rafts and 415 
elicits plasma membrane fusion (31) that results severely impaired using 416 
chemical inhibitors of this protease (10, 11). Apart from TMPRSS2, the lysosomal 417 
proteases, specifically cathepsin L, are crucial for SARS-CoV-2 entry via endo-418 
lysosomes (11). Both, TMPRSS2 and cathepsin L proteases have cumulative 419 
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effects along with the cleavage caused by furin at the Golgi (subsequent to S-420 
protein synthesis during viral packaging) on activating SARS-CoV-2 entry and 421 
penetration in the cytoplasm. 422 
SARS-CoV-2 would traffic the endocytic pathway inside the early and late 423 
endosomal vesicles to finally fuse with lysosomes, an essential stage for viral 424 
uncoating and fusion (31). According to that, viral infection is abrogated by drugs 425 
interfering endosome acidification (11). Also, SARS-CoV-2 pseudovirions 426 
infection is inhibited using drugs targeting the late endosomal compartments, like 427 
cathepsin L, two-pore channel 2 (TPC2), or PIKfyve. Inhibitors against these 428 
proteins dramatically reduce infection, indicating that TPC2, cathepsin L, 429 
endosomal maturation, and endosomal acidic luminal pH, are crucial host factors 430 
for endocytosed SARS-CoV2 entry (11, 35). Thus, late endosomes/lysosomes 431 
are proposed as relevant organelles to develop therapeutic targets against 432 
infection by SARS-CoV-2 (8, 11, 31-34, 48).  433 
A recent study discovered that SARS-CoV-2 non-structural protein 7 (nsp7) 434 
strongly interacts with Rab7a, and its depletion causes retention of ACE2 435 
receptor inside late endosomes (45). Other reports highlighted the relevance of 436 
a variety of proteins involved in cholesterol biosynthesis, including NPC1 infection 437 
(32). Also, the cholesterol biosynthesis pathway is downregulated during SARS-438 
CoV-2 infection and, according to that, drug treatments that regulate this pathway 439 
impact the infection (49).  440 
Here, we described in this study an interaction between SARS-CoV-2 N protein 441 
and NPC1. This interaction unveiled a novel host-based target for antivirals and 442 
a potential host factor for SARS-CoV-2 infectivity. As in other viruses, this 443 
interaction could possibly regulate and modify cholesterol efflux from late 444 
endosomes and alter the lipid composition in cellular membranes in its own 445 
benefit (50). Besides, we presented data on how several compounds that block 446 
NPC1 function severely impact 229E HCoV infection in a functional assay, which 447 
suggests an essential role for NPC1 in HCoV infectivity.  448 
Small molecule inhibitors were crucial to determine that NPC1 was essential for 449 
EBOV infection (22). Compounds MBX2254, an aminoacetamide sulfonamide, 450 
and MBX2270, a triazole thioether were reported to inhibit EBOV infection with 451 
high selectivity (41). All those compounds have NPC1 as a target and we found 452 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted December 20, 2020. ; https://doi.org/10.1101/2020.12.19.423584doi: bioRxiv preprint 
 17 
that those chemicals strongly inhibited HCoV 229E infection. Also, compounds 453 
found using the NPC1/EBOV-GP interaction for the screening of a library of 454 
compounds, namely sulfides, carbazoles and benzothiazepines (shown in Figure 455 
2), were tested for HCoV inhibition. We have shown that compounds that 456 
inhibited EBOV-GP/NPC1 binding, namely sulfides SC073 and SC198 together 457 
with carbazole SC816, and not others, presented a potent inhibition of 229E-CoV 458 
infection. These chemicals have been shown to inhibit EBOV binding to NPC1 459 
and the infection of EBOV-GP pseudovirions elsewhere (40). We have shown 460 
here that those compounds that were able to inhibit EBOV-GP/NPC1 binding 461 
were also capable to inhibit SARS-CoV-2 N protein/NPC1 binding in an ELISA 462 
assay. 463 
To conclude, according to other authors and recent evidences (31-34, 49), we 464 
propose NPC1 as a potential therapeutic target for SARS-CoV-2 to combat 465 
COVID-19 pandemic. We show for first-time experimental evidences of the 466 
binding of SARS-CoV-2 Nucleoprotein (N) to NPC1. This important finding paves 467 
the way to direct medical efforts and therapeutics to NPC1 and to continue 468 
studies on cholesterol metabolism in SARS-CoV-2 infection. 469 
 470 
 471 
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Supplementary Figure S1A: Membranes used to compose the figure 1C. Dashed boxes were taken to 511 
create the western blot composition showed in the figure. Membrane 1 triplicates revealed with rabbit anti-512 
NPC1 antibody, membrane 2 triplicates revealed with mouse anti-GFP antibody and membrane 2 revealed 513 
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518 
Supplementary Figure S1B (cont): Membrane used to compose the figure 1C. Dashed boxes were taken 519 
to create the western blot composition showed in the figure. Original membrane.  520 
 521 
Supplementary Figure S2: Membranes used to compose the figure 1D. Dashed boxes were taken to create 522 
the western blot composition showed in the figure. Original membrane 1 developed with Mouse anti-GFP 523 
antibody, membrane 2 developed with Rabbit anti-NPC1 antibody and membrane 3 developed with Rat anti-524 
HSP90 antibody. 525 
 526 
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 527 
Supplementary Figure S3: Cell viability under chemicals treatment 528 
Cell viability measured after 24 hours incubation of Huh-7 cells with each compound at concentrations 529 
ranging from 0-100 µM in DMEM. Absorbance was measured at 490 nm using an ELISA plate reader. Y 530 
axis depicts median and standard deviations of the percentages of absorbance in compound treated cells 531 






Supplementary Figure S4: Dose-response curves of the compounds used. Dose-response curves with 538 
increasing concentrations of compounds at ranges selected depending on working concentrations for each 539 
compound. 540 
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